Global CRM197 Market Size By Type (Research Grade CRM197 and cGMP Grade CRM197), By Application (Meningococcal Polysaccharide Conjugate Vaccine, Pneumococcal Conjugate Vaccine), By Geographic Scope And Forecast

CRM197 Market Size And Forecast

CRM197 Market size was valued at USD 171.4 Million in 2021 and is projected to reach USD 277.51 Million by 2030, growing at a CAGR of 5.5% from 2023 to 2030.

CRM197 is supporting several crucial vaccinations that could play a key role in preventing deadly infections including meningitis and pneumonia. This, in turn, will boost market growth. The Global CRM197 Market report provides a holistic evaluation of the market. The report offers a comprehensive analysis of key segments, trends, drivers, restraints, competitive landscape, and factors that are playing a substantial role in the market.

Global CRM197 Market Definition

CRM197 is now employed as a carrier protein for polysaccharides and helps to render them immunogenic. It is a non-toxic variant of diphtheria toxin. There is significant debate over CRM197’s toxicity, however there is evidence that it is poisonous to several mammalian cell lines and yeast cells. CRM197 is a diphtheria toxin that has undergone genetic detoxification. The ADP-ribosyltransferase activity of the native toxin is lost as a result of a single mutation at position 52, where glutamic acid is substituted for glycine. Recently, the structural underpinnings of CRM197’s lack of toxicity were revealed. As a carrier protein for conjugate vaccines, CRM197 is frequently utilised.

As CRM197 is genetically detoxified and retains its entire complement of lysine amines for conjugation, it may have an advantage over toxoided proteins. Additionally, there is evidence that suggests there is less carrier-induced immune response suppression as compared to tetanus toxoid, particularly when there are numerous different polysaccharides connected to the same carrier protein. There has been published a summary of CRM197’s features and usage. Similar to diphtheria toxin, CRM197 is a single, 535 amino acid, 58.4 kD polypeptide chain made up of two subunits (linked by disulfide bridges).

Many licenced conjugate vaccines use CRM197 as a carrier protein. The first conjugate vaccine to use CRM197 was HibtiterTM, a vaccine against Haemophilus influenzae type b that was authorised by the FDA in 1990. The first pneumococcal conjugate vaccination to receive FDA approval was Pfizer’s Prevnar, which contains CRM197-conjugated polysaccharides from various pneumococcal serotypes. Numerous conjugate vaccines using CRM197 as the carrier protein are now being tested in both clinical and pre-clinical settings. Menveo, a meningitis ACWY vaccine made by GlaxoSmithKline, is another instance of a CRM197 conjugate vaccine that is now in use. Additionally, the Pelican Expression Technology platform-produced CRM197 is utilised by Merck in the VAXNEUVANCE and Serum Institute’s Pneumosil.

Global CRM197 Market Overview

CRM197 is supporting several crucial vaccinations that could play a key role in preventing deadly infections including meningitis and pneumonia. As a result, this collaboration will aid in the development of affordable, essential vaccines, while FinaBio maintains the worldwide commercialization rights for EcoCRM, including exclusive rights outside of low-income nations and indications for non-infectious diseases.

Pneumococcal and meningococcal vaccines as well as several vaccines currently under development, such as those for Group B Streptococcus, Salmonella, Klebsiella, and malaria, frequently use CRM197, a genetically detoxified diphtheria toxin.

It is incorporated into Pfizer’s Prevnar 13, the most popular vaccination in the world and the only pneumococcal conjugate vaccine authorised in the US. In order to boost the immune response to the antigen, CRM197 is chemically joined (“conjugated”) to the antigen of interest as a component of these vaccines. One of the most intricate and pricey paediatric vaccinations available today is the conjugate vaccine.

Hundreds of millions of kids have been successfully immunised with vaccines that contain CRM197 as a carrier protein. A new tetravalent conjugate vaccine called Menveo, Menjugate and Meningitec (against serotype C of Neisseria meningitidis), Vaxem-Hib and HibTITER (against Haemophilus influenzae type B, Hib), and the multivalent pneumococcal conjugate Prevnar are examples of this type of vaccination.

Global CRM197 MarketSegmentation Analysis

The Global CRM197 Market is segmented based on Type, Application, And Geography.

CRM197 Market, By Type

• Research Grade CRM197• cGMP Grade CRM197

Based on Type, the market is segmented into Research Grade CRM197 and cGMP Grade CRM197.

CRM197 Market, By Application

• Pneumococcal Conjugate Vaccine• Meningococcal Polysaccharide Conjugate Vaccine• Others

Based on Application, the market is segmented into Meningococcal Polysaccharide Conjugate Vaccine, Pneumococcal Conjugate Vaccine, and others.

CRM197 Market, By Geography

• North America• Europe• The Asia Pacific• Rest of the world

Based on regional analysis, the Global CRM197 Market is classified into North America, Europe, Asia Pacific, and the Rest of the world.

Key Players

The major players in the Global “CRM197 Market” are Pfizer Inc., Fina Biosolutions, Eubiologics, EirGenix Inc., Xpress Biologics, and Ligand Pharmaceuticals. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

Key Developments

• August 2020Pfenex and Merck signed a research and collaboration agreement to evaluate a specified set of proteins to be produced through the Pfenex Expression Technology platform. Under the terms of the arrangement, Pfenex will receive an upfront payment in the amount of $2.5 million dollars and research funding.

Report Scope

Top Trending Reports

Research Methodology of Market Research

To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our .

Reasons to Purchase this Report

• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors• Provision of market value (USD Billion) data for each segment and sub-segment• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled• Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players• The current as well as the future market outlook of the industry with respect to recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions• Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis• Provides insight into the market through Value Chain• Market dynamics scenario, along with growth opportunities of the market in the years to come• 6-month post-sales analyst support

Customization of the Report

• In case of any  please connect with our sales team, who will ensure that your requirements are met.